AnaptysBio Priced, Nasdaq: ANAB

Early-stage biotech developing antibodies for severe inflammatory conditions.

Industry: Health Care

Latest Trade: $34.53 0.00 (0.0%)

First Day Return: +13.3%

Return from IPO: +130.2%

Industry: Health Care

We are a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights.
more less
IPO News for AnaptysBio
more
IPO Data
IPO File Date 09/09/2015
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
IPO Data
IPO Date 01/25/2017
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2005
Employees 49
Website www.anaptysbio.com